Clinical Trial: Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07874581) titled 'Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC' on Oct. 08.

Brief Summary: This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer. Eligible patients receive becotatug vedotin at a dose of 2.3 mg/kg administered by intravenous infusion once every 21 days until disease progression or unacceptable toxicity. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and safety.

Study Start Date: Oct. 01

Study T...